Cystic fibrosis-related bone disease: Insights into a growing problem

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 6, 2013, Pages 547-552

  Stalvey, Michael S ^a   Clines, Gregory A ^b,c  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Bone disease; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; Fracture

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCITRIOL; CALCIUM; CORTICOSTEROID; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; CYTOKINE; DENOSUMAB; GLUCOCORTICOID; GROWTH HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; SEX HORMONE; SOMATOMEDIN C; VITAMIN D;

ANTIBODY SPECIFICITY; BODY MASS; BODY WEIGHT; BONE AGE; BONE BIOPSY; BONE DENSITY; BONE DISEASE; BONE MARROW CULTURE; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE PAIN; BONE TURNOVER; CALCIUM ABSORPTION; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CELL DIFFERENTIATION; COMPRESSION FRACTURE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; CYSTIC FIBROSIS RELATED BONE DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSGLYCEMIA; ENCHONDRAL OSSIFICATION; FLU LIKE SYNDROME; HORMONE RESPONSE; HORMONE SYNTHESIS; HUMAN; HYPERGLYCEMIA; HYPOGONADISM; IMMUNOHISTOCHEMISTRY; INTESTINE; INTRACELLULAR SIGNALING; LIFE EXPECTANCY; LUNG DISEASE; LUNG FUNCTION; MALNUTRITION; NONHUMAN; NUTRITION; ORAL GLUCOSE TOLERANCE TEST; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PANCREAS INSUFFICIENCY; PATHOGENESIS; PATHOLOGIC FRACTURE; PREDICTIVE VALUE; PRIMARY CELL CULTURE; PROTEIN EXPRESSION; RESPIRATORY DISTRESS; REVIEW; RISK FACTOR; SHORT STATURE; SPINE FRACTURE; UPREGULATION; URINE LEVEL; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ABSORPTIOMETRY, PHOTON; BONE DISEASES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; MALE; MASS SCREENING; QUALITY OF LIFE; VITAMIN D DEFICIENCY;

EID: 84890016989     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/01.med.0000436191.87727.ec     Document Type: Review

References (43)

1. Cystic Fibrosis Foundation Patient Registry. Annual data report. Bethesda, MD; 2012. A detailed account of the CF Foundation Patient Registry, with data on incidence of comorbidities in CF.
2. Orenstein DM, WinnieGB, Altman H. Cystic fibrosis: a 2002 update. J Pediatr 2002; 140:156-164.
3. Mischler EH, Chesney PJ, Chesney RW, Mazess RB. Demineralization in cystic fibrosis detected by direct photon absorptiometry. Am J Dis Child 1979; 133:632-635.
4. Aris RM, Renner JB, Winders AD, et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med 1998; 128:186-193.
5. Rovner AJ, Zemel BS, Leonard MB, et al. Mild to moderate cystic fibrosis is not associated with increased fracture risk in children and adolescents. J Pediatr 2005; 147:327-331.
6. Latzin P, Griese M, Hermanns V, Kammer B. Sternal fracture with fatal outcome in cystic fibrosis. Thorax 2005; 60:616.
7. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005; 90:1888-1896.
8. Stalvey MS, Flotte TR. Endocrine parameters of cystic fibrosis: back to basics. J Cell Biochem 2009; 108:353-361.
9. King SJ, Topliss DJ, Kotsimbos T, et al. Reduced bone density in cystic fibrosis: DeltaF508 mutation is an independent risk factor. Eur Respir J 2005; 25:54-61.
10. Boyle MP. Update on maintaining bone health in cystic fibrosis. Curr Opin Pulm Med 2006; 12:453-458.
11. De Schepper J, Roggen I, Van Biervliet S, et al. Comparative bone status assessment by dual energy X-ray absorptiometry, peripheral quantitative computed tomography and quantitative ultrasound in adolescents and young adults with cystic fibrosis. J Cyst Fibros 2012; 11:119-124. An evaluation of quantitative ultrasound for the screening and diagnosis of CFBD.
12. Haworth CS, Webb AK, Egan JJ, et al. Bone histomorphometry in adult patients with cystic fibrosis. Chest 2000; 118:434-439.
13. Aris RM, Ontjes DA, Buell HE, et al. Abnormal bone turnover in cystic fibrosis adults. Osteoporos Int 2002; 13:151-157.
14. Aris RM, Lester GE, Dingman S, Ontjes DA. Altered calcium homeostasis in adults with cystic fibrosis. Osteoporos Int 1999; 10:102-108.
15. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoidinduced osteoporosis. Endocrinology 1999; 140:4382-4389.
16. DiMango E, Ratner AJ, Bryan R, et al. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998; 101:2598-2605.
17. Ionescu AA, Nixon LS, Evans WD, et al. Bone density, body composition, and inflammatory status in cystic fibrosis. Am J Respir Crit Care Med 2000; 162 (3 Pt 1):789-794.
18. Haworth CS, Selby PL, Webb AK, et al. Inflammatory related changes in bone mineral content in adults with cystic fibrosis. Thorax 2004; 59:613-617.
19. Shead EF, Haworth CS, Gunn E, et al. Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis. Am J Respir Crit Care Med 2006; 174:306-311.
20. Moran A, Becker D, Casella SJ, et al. Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review. Diabetes Care 2010; 33:2677-2683.
21. Botolin S, McCabe LR. Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology 2007; 148:198-205.
22. Hamilton EJ, Rakic V, Davis WA, et al. Prevalence and predictors of osteopenia and osteoporosis in adults with Type 1 diabetes. Diabet Med 2009; 26:45-52.
23. Vestergaard P, Rejnmark L, Mosekilde L. Diabetes and its complications and their relationship with risk of fractures in type 1 and 2 diabetes. Calcif Tissue Int 2009; 84:45-55.
24. Rana M, Munns CF, Selvadurai H, et al. The impact of dysglycaemia on bone mineral accrual in young people with cystic fibrosis. Clin Endocrinol (Oxf) 2013; 78:36-42. A retrospective comparison of DXA results and dysglycemia in young CF individuals.
25. Laursen EM, Lanng S, Rasmussen MH, et al. Normal spontaneous and stimulated GHlevels despite decreased IGF-I concentrations in cystic fibrosis patients. Eur J Endocrinol 1999; 140:315-321.
26. Rosenberg LA, Schluchter MD, Parlow AF, Drumm ML. Mouse as a model of growth retardation in cystic fibrosis. Pediatr Res 2006; 59:191-195.
27. Gordon CM, Binello E, LeBoff MS, et al. Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis. Osteoporos Int 2006; 17:783-790.
28. Stead RJ, Hodson ME, Batten JC, et al. Amenorrhoea in cystic fibrosis. Clin Endocrinol (Oxf) 1987; 26:187-195.
29. Leifke E, Friemert M, Heilmann M, et al. Sex steroids and body composition in men with cystic fibrosis. Eur J Endocrinol 2003; 148:551-557.
30. Rossini M, Del Marco A, Dal Santo F, et al. Prevalence and correlates of vertebral fractures in adults with cystic fibrosis. Bone 2004; 35:771-776.
31. Dif F, Marty C, Baudoin C, et al. Severe osteopenia in CFTR-null mice. Bone 2004; 35:595-603.
32. Haston CK, Li W, Li A, et al. Persistent osteopenia in adult cystic fibrosis transmembrane conductance regulator-deficient mice. Am J Respir Crit Care Med 2008; 177:309-315.
33. Pashuck TD, Franz SE, Altman MK, et al. Murine model for cystic fibrosis bone disease demonstrates osteopenia and sex-related differences in bone formation. Pediatr Res 2009; 65:311-316.
34. Le Henaff C, Gimenez A, Hay E, et al. The F508del mutation in cystic fibrosis transmembrane conductance regulator gene impacts bone formation. Am J Pathol 2012; 180:2068-2075.
35. Snouwaert JN, Brigman KK, Latour AM, et al. An animal model for cystic fibrosis made by gene targeting. Science 1992; 257:1083-1088.
36. Snouwaert JN, Brigman KK, Latour AM, et al. A murine model of cystic fibrosis. Am J Respir Crit Care Med 1995; 151 (3 Pt 2):S59-S64.
37. Shead EF, Haworth CS, Condliffe AM, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 2007; 62:650-651.
38. Stalvey M, Clines K, Havasi V, et al. Osteoblast CFTR Inactivation Reduces Differentiation and Osteoprotegerin Expression in a Mouse Model of Cystic Fibrosis-Related Bone Disease. PLOS ONE (In press). An in-vitro analysis of the direct and indirect actions of CFTER on osteoblasts and osteoclasts.
39. Ferguson JH, Chang AB. Vitamin D supplementation for cystic fibrosis. Cochrane Database Syst Rev 2012; 4:CD007298. A comparison of multiple clinical trials of vitamin D supplimentation in CF.
40. Tangpricha V, Kelly A, Stephenson A, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab 2012; 97:1082-1093. A CF guidelines committee review of the evaluation and treatment of vitamin D in individuals with CF.
41. Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev 2012; 4:CD002010. A comparison of multiple clinical trials of bisphosphonate therapy in CF.
42. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349:1207-1215.
43. Hardin DS, Ahn C, Prestidge C, et al. Growth hormone improves bone mineral content in children with cystic fibrosis. J Pediatr Endocrinol Metab 2005; 18:589-595.